Kyungdong Pharm
KOSDAQ:011040
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/FCFE
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Valuation Scenarios
If P/FCFE returns to its Industry Average (23.2), the stock would be worth ₩-4 709.86 (184% downside from current price).
| Scenario | P/FCFE Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -27.8 | ₩5 640 |
0%
|
| Industry Average | 23.2 | ₩-4 709.86 |
-184%
|
| Country Average | 15.1 | ₩-3 052.89 |
-154%
|
Forward P/FCFE
Today’s price vs future free cash flow to equity
Peer Comparison
| Market Cap | P/FCFE | P/E | ||||
|---|---|---|---|---|---|---|
| KR |
K
|
Kyungdong Pharm
KOSDAQ:011040
|
173.5B KRW | -27.8 | 18.4 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
910.2B USD | 67.4 | 44.1 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.1B USD | 21 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 27.5 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
209.6B GBP | 36.2 | 27.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
221.1B CHF | 9.4 | 20.7 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
277.6B USD | 12.3 | 15.2 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | -766.6 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 24.3 | 12.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
149.7B USD | 24.3 | 19.3 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
117.2B USD | 19.3 | 16.6 |
Market Distribution
| Min | 0.2 |
| 30th Percentile | 8.1 |
| Median | 15.1 |
| 70th Percentile | 28.4 |
| Max | 21 200 |
Other Multiples
Kyungdong Pharm
Glance View
KYUNG DONG PHARMACEUTICAL Co., Ltd. engages in the manufacture and sale of medicines for liver therapy, gastrointestinal, antimigrain, osteoporosis, cardiovascular, antiviral, antiobesity, muscle relaxant, neuropathic, antibacterial, antidiabetic, central nervous system, antifungal, urology, antispasmodic, pain and inflammation, antihistamine, vitamin, repiratory, antiinflammatory enzyme, respiratory and others. The company is headquartered in Hwaseong, Gyeonggi-Do. is a Korea-based company engaged in the manufacture and marketing of pharmaceutical products. The Company’s products include liver therapies, gastrointestinal drugs, antimigraine drugs, antiviral, anti-obesity medications, antibacterial drugs, antidiabetic drugs, antifungal, allergy medications, antispasmodics, antihistamines, vitamins, as well as drugs for osteoporosis, cardiovascular, muscle relaxant, neuropathic and other diseases. The company also provides various over-the-counter (OTC) drugs, such as anti-inflammatory medicines, antiviral drugs, antihistamine drugs, gastrointestinal drugs and others. In addition, the Company engages in the leasing of real estate, and distribution of snowboards and health functional food.
